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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016with end stage renal failure (ESRF ) on HD and burdened with
chronic viral hepatitis C (HCV).
Methods: Cytogenetic examination was performed in three patients
groups: 23 patients with ESRF on HD; 21 patient having HCV with
ESRF on HD; 29 patients with HCV without renal function disorder.
Lymphocytes were cultivated according to the conventional Hun-
gerford method for 52 hours with modiﬁcations. Selection of met-
aphasal plates for cytogenetic analysis, classiﬁcation and method for
calculation of chromosome aberrations were conventional. Multi-
aberrant cells were considered those having 3 aberrations and more.
Aneuploid cells were divided into hypoploid (under 42) and hy-
perploid ones (over 49).
Results: The frequency of chromosome aberrations was conﬁdently
different in all the three groups of patients examined and exceeded
the norm (by 3%). The highest indexes were in patients with HCV
(17,78  0,55%, P < 0,05) which was the cosequence of virus-
induced mutagenesis and were conﬁrmed by the data of other
authors. An intermidiate result (10,60  1,49%, P < 0,05) of chro-
mosome aberrations frequency in patients having HCV with ESRF
might suggest the impact of HD procedure on the chronic hepatitis
ﬂow in this patients’ category. In patients with ESRF this index was
conﬁdently lower than in other patients groups (4,69  0,51%).
In patients with ESRF on HD a number of aneuploid cells was
conﬁdently higher (20,0  0,97%, P < 0,05) and hence one may
suppose the presence of oncogenic component. In patients group with
HCV on HD and those without renal function disorder this index was
lower and made 14,12  1,69% and 16,32  0,53% accordingly. The
virus in case of a durable replicative phase is an inductor of a chain of
events leading to severe and mass demages of chromosome material.
This is conﬁrmed by the highest level of multiaberrant cells 7,71 
0,38% in patients with HCV. In patients with HCV on HD a number
of multiaberrant cells was conﬁdently lower and made 2,35  0,74%,
which didn’t differ from the indexes of patients with ESRF on HD
without hepatitis. In patients with HCV the largest chromosome
aberration spectrum was ﬁxed, that included acentric rings and
translocations, indicating its virus-induced damages.
A single hemodialysis procedure had no impact on the chro-
mosome aberrations level: the frequency of metaphases with aber-
rations remained on pre-dialysis level.
Conclusions:Hemodialysis procedure has an effect on the HCV ﬂow
and neutralizes the virus impact on genetic apparatus in case of
those pathologies combined. Our data allow one to explain and
conﬁrm the results of other researchers stating that the HCV ﬂow in
patients on program hemodialysis is less aggressive.
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Introduction: Chronic kidney disease (CKD) affects 8-16% people
worldwide, with an increasing incidence and prevalence of end-
stage kidney disease (ESKD). The effective management of CKD is
currently confounded by the inability to identify patients at high
risk of progression while still in early stages of CKD. Identifying the
mechanism responsible for progression of CKD is a critical step to
contain the worldwide CKD epidemic. A molecular disease deﬁni-
tion of CKD will allow us to develop strategies for patient risk
stratiﬁcation to prioritize limited health care resources, to identify
targeted molecular therapies for patients at high risk and to develop
biomarkers to deﬁne such patients for clinical trials. Our hypothesis
is that both clinical phenotypes (e.g. GFR, proteinuria) and renal
tissue alterations seen in CKD are associated with, and a conse-
quence of, the dynamic molecular mechanism reﬂected in the
transcriptional programs of the diseased renal tissue.
Methods: Our work started from the identiﬁcation and cross-vali-
dation of pathways and candidate intrarenal biomarkers for CKD
progression in 261 kidney biopsies. We then used a sequential
prioritization strategy to prioritize candidates for non- invasive
biomarkers to allow broad clinical applicability. Next, intra-renal
transcript levels of the top candidate biomarker were correlated
with the urinary levels of the encoded proteins. Urinary protein
levels were assessed for their correlation with CKD progression.
Finally, the biomarker was tested for its ability to increase pre-
dictive power of established clinical marker panels for CKD pro-
gression prediction in three cohorts. We used Cox proportional
hazards models to evaluate the predictive value of marker on CKD
outcome, and used likelihood ratio tests, C-statistics, and Akaike
information criterion (AIC) to assess the goodness of ﬁt and
improved prediction ability. Finally, we present our effort in
identiﬁcation the molecular disease mechanism, serving as targets,
to develop novel therapies to prevent CKD progression.
Results: Using Epidermal Growth Factor (EGF) as a proof of prin-
ciple, we could demonstrate that prediction of renal survival by
eGFR and albuminuria was signiﬁcantly improved by addition of
uEGF to the model in diverse CKD populations with a wide spec-
trum of causes and stages. uEGF may contribute to the improved
risk prediction as it can capture the degree of tubular differentia-
tion and regeneration potential, mechanisms essential to retain renal
function with the acute and chronic insults seen in CKD, but not be
well reﬂected by the conventional predictors (proteinuria or base-
line GFR).
Conclusions: uEGF shows promise as an independent risk predictor
of CKD progression. Inclusion of uEGF signiﬁcantly improved
prediction of composite end points by eGFR and proteinuria in
diverse populations worldwide with a wide range of CKD. An
immediate beneﬁt of our work can be an improved stratiﬁcation of
CKD patients for the selections of high-risk patients into clinical
trials, addressing a critical hurdle for novel molecular target vali-
dation in CKD.
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